Last reviewed · How we verify

Acofide (ACOTIAMIDE)

Zeria · FDA-approved active Small molecule Quality 17/100

Acofide (generic name: ACOTIAMIDE) is a Small molecule drug developed by Zeria. It is currently FDA-approved for Nonulcer dyspepsia.

ACOTIAMIDE (Acofide), marketed by Zeria, is a nonulcer dyspepsia treatment that inhibits acetylcholinesterase, positioning it in a competitive market alongside metoclopramide and cisapride. Acofide's key strength lies in its distinct mechanism of action, which differentiates it from same-class competitors like metoclopramide and cisapride. The primary risk to Acofide is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic nameACOTIAMIDE
SponsorZeria
TargetAcetylcholinesterase
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Acofide

What is Acofide?

Acofide (ACOTIAMIDE) is a Small molecule drug developed by Zeria, indicated for Nonulcer dyspepsia.

What is Acofide used for?

Acofide is indicated for Nonulcer dyspepsia.

Who makes Acofide?

Acofide is developed and marketed by Zeria (see full Zeria pipeline at /company/zeria).

What is the generic name of Acofide?

ACOTIAMIDE is the generic (nonproprietary) name of Acofide.

What development phase is Acofide in?

Acofide is FDA-approved (marketed).

What does Acofide target?

Acofide targets Acetylcholinesterase.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing